Longevity Acquisition logo

LOACU - Longevity Acquisition News Story

$14.99 0.0  0.0%

Sector
Financials
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6841

BRIEF-Longevity Acquisition Announces 4D Pharma Clinical Trial Collaboration And Supply Agreement For Treatment Of Locally Advanced Or Metastatic Urothelial Carcinoma

Mon 8th February, 2021 1:05pm
Feb 8 (Reuters) - Longevity Acquisition Corp  LOACU.O :
    * LONGEVITY ACQUISITION CORPORATION ANNOUNCES 4D PHARMA
CLINICAL
TRIAL COLLABORATION AND SUPPLY AGREEMENT FOR THE TREATMENT OF
LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
    * LONGEVITY ACQUISITION - 4D PHARMA INTENDS TO COMMENCE A
CLINICAL
TRIAL IN 2021 TO EVALUATE BAVENCIO IN COMBINATION WITH MRX0518

Source text for Eikon:  ID:nPn7k8yC3a 
Further company coverage:  LOACU.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.